Evgen Pharma PLC AGM Statement (0764M)
July 26 2017 - 2:00AM
UK Regulatory
TIDMEVG
RNS Number : 0764M
Evgen Pharma PLC
26 July 2017
For immediate release 26 July 2017
Evgen Pharma plc
("Evgen Pharma" or "the Company")
AGM Statement
Evgen Pharma (AIM: EVG), a clinical stage drug development
company focused on the treatment of cancer and neurological
conditions, will hold its Annual General Meeting ("AGM") this
afternoon in Manchester. At the AGM, the Company's Chairman, Barry
Clare, will make the following statement:
"The current year is progressing well for our Company. SFX-01,
our lead product candidate, continues to be tested in two Phase II
trials in different indications, breast cancer and subarachnoid
haemorrhage.
"Interest in SFX-01 and sulforaphane-based science continues
apace in the academic and translational medicine communities.
Earlier this month, we announced that the Manchester Cancer
Research Centre will conduct preclinical research of SFX-01 in
triple negative breast cancer. Today, we can announce that the
Company and the Skeletal Biology Group at the Royal Veterinary
College ("RVC"), University of London, has secured grant funding to
continue its collaboration and build on earlier encouraging
preclinical results demonstrating the potential of SFX-01 as a
treatment for osteoarthritis. The RVC will be releasing a separate
announcement later today.
"These investigator-led studies underline the broad therapeutic
potential of SFX-01 and extend the Company's commercial presence in
sulforaphane-based research. Our primary focus remains on our two
Phase II trials and we look forward to making further progress with
these trials in the year ahead."
Dr Stephen Franklin, Evgen Pharma's CEO, will give a corporate
presentation at the AGM. A copy of the presentation is available at
the Company's website, www.evgen.com.
Enquiries:
Evgen Pharma plc c/o +44 (0) 20 7466
Dr Stephen Franklin, CEO 5000
Richard Moulson, CFO
www.evgen.com
Buchanan
Mark Court, Sophie Cowles, Stephanie +44 (0) 20 7466
Watson 5000
Northland Capital Partners Limited
Matthew Johnson, Gerry Beaney,
Margarita Mitropoulou (Corporate
Finance)
John Howes, Rob Rees (Corporate +44 (0) 20 3861
Broking) 6625
Notes for editors:
About Evgen Pharma plc
Evgen Pharma is a clinical stage drug development company whose
lead programmes are in breast cancer and subarachnoid haemorrhage,
a type of stroke. It is also carrying out preclinical work in
multiple sclerosis and has a clinical interest in prostate cancer.
The Company's core technology is Sulforadex(R), a method for
synthesising and stabilising the naturally occurring compound
sulforaphane and novel proprietary analogues based on sulforaphane.
The lead product, SFX-01, is a patented composition of synthetic
sulforaphane and alpha-cyclodextrin.
Evgen Pharma commenced operations in January 2008 and has its
headquarters at The Colony, Wilmslow, Cheshire, and its registered
office is at the Liverpool Science Park, Liverpool. It joined the
AIM market of the London Stock Exchange in October 2015 and trades
under the ticker symbol EVG.
For further information, please visit: www.evgen.com
For commissioned research on the Company, please visit:
http://evgen.com/investors/analyst-coverage/
This information is provided by RNS
The company news service from the London Stock Exchange
END
AGMEAKXSALDXEFF
(END) Dow Jones Newswires
July 26, 2017 02:00 ET (06:00 GMT)
Evgen Pharma (LSE:EVG)
Historical Stock Chart
From Apr 2024 to May 2024
Evgen Pharma (LSE:EVG)
Historical Stock Chart
From May 2023 to May 2024